VASTox receives grant form European neuromuscular disease charity

03-Nov-2006

VASTox has received a grant from the Association Francaise Contre Les Myopathies (AFM), a European neuromuscular disease charity, to support to the company's Spinal Muscular atrophy (SMA) drug discovery programme.

VASTox has developed an in vivo screen, which models SMA in fruitfly larvae (Drosophila melanogaster). The Company is using this model to identify small molecules from its proprietary compound library. The financial support from AFM will allow VASTox to accelerate the preclinical screening and candidate identification phase of the programme and consequently aid the development of a novel therapy for SMA.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances